Search
Results: 55524
Best practice in Active Surveillance for men with prostate cancer
Samuel WD Merriel, Liz Hetherington, Andrew Seggie, Joanna T Castle, William Cross, Monique J Roobol, Vincent Gnanapragasam, Caroline M Moore, Prostate Cancer UK Expert Reference Group on Active Surveillance
Apr 04, 2019
OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS: A consensus statement was drafted on the basis of...
Active surveillance of prostate cancer
BACKGROUND: Active surveillance is considered a mainstream strategy in the management of patients with low-risk prostate cancer. A mission-critical step in implementing a robust active surveillance program and plan its resource...
Consensus for genes to be included on cancer panel tests offered by UK genetics services
Amy Taylor, Angela F Brady, Ian M Frayling, Helen Hanson, Marc Tischkowitz, Clare Turnbull, Lucy Side, UK Cancer Genetics Group (UK-CGG)
May 18, 2018
Genetic testing for hereditary cancer predisposition has evolved rapidly in recent years with the discovery of new genes, but there is much debate over the clinical utility of testing genes for which there are currently limited...
Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome.
Marc Tischkowitz, Chrystelle Colas, Sjaak Pouwels, Nicoline Hoogerbrugge, PHTS Guideline Development Group, European Reference Network GENTURIS
Apr 29, 2020
PTEN hamartoma tumour syndrome is a diverse multi-system disorder predisposing to the development of hamartomatous growths, increasing risk of breast, thyroid, renal cancer, and possibly increasing risk of endometrial cancer...
Homeobox B13 G84E Mutation and Prostate Cancer Risk.
Tommy Nyberg, Koveela Govindasami, Goska Leslie, Tokhir Dadaev, Elizabeth Bancroft, Holly Ni Raghallaigh, Mark N Brook, Nafisa Hussain, Diana Keating, Andrew Lee, Romayne McMahon, Angela Morgan, Andrea Mullen, Andrea Osborne, Reshma Rageevakumar, UK Genetic Prostate Cancer Study Collaborators, Zsofia Kote-Jarai, Rosalind Eeles, Antonis C Antoniou
Dec 19, 2018
BACKGROUND: The homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutation is uncertain. OBJECTIVE: To obtain...
Surveillance recommendations for DICER1 pathogenic variant carriers
Jette J Bakhuizen, Helen Hanson, Karin van der Tuin, Fiona Lalloo, Marc Tischkowitz, Karin Wadt, Marjolijn CJ Jongmans, SIOPE Host Genome Working Group, CanGene-CanVar Clinical Guideline Working Group, Expert Network Members
Oct 01, 2021
DICER1 syndrome is a rare genetic disorder that predisposes to a wide spectrum of tumors. Developing surveillance protocols for this syndrome is challenging because uncertainty exists about the clinical efficacy of surveillance...
Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer.
Vincent J Gnanapragasam, Tristan Barrett, Vineetha Thankapannair, David Thurtle, Jose Rubio-Briones, Jose Domínguez-Escrig, Ola Bratt, Par Statin, Kenneth Muir, Artitaya Lophatananon
May 10, 2019
OBJECTIVES: To test whether using disease prognosis can inform a rational approach to active surveillance (AS) for early prostate cancer. PATIENTS AND METHODS: We previously developed the Cambridge Prognostics Groups (CPG)...
Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
Sian M. Noble, Kirsty Garfield, J. Athene Lane, Chris Metcalfe, Michael Davis, Eleanor I. Walsh, Richard M. Martin, Emma L. Turner, Tim J. Peters, Joanna C. Thorn, Malcolm Mason, Prasad Bollina, James W. F. Catto, Alan Doherty, Vincent Gnanapragasam, Owen Hughes, Roger Kockelbergh, Howard Kynaston, Alan Paul, Edgar Paez, Derek J. Rosario, Edward Rowe, Jon Oxley, John Staffurth, David E. Neal, Freddie C. Hamdy, Jenny L. Donovan
Feb 09, 2021
Abstract: Background: There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer. Methods: The cost-effectiveness of active monitoring, surgery, and radiotherapy was evaluated within...
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
Sian M. Noble, Kirsty Garfield, J. Athene Lane, Chris Metcalfe, Michael Davis, Eleanor I. Walsh, Richard M. Martin, Emma L. Turner, Tim J. Peters, Joanna C. Thorn, Malcolm Mason, Prasad Bollina, James W. F. Catto, Alan Doherty, Vincent Gnanapragasam, Owen Hughes, Roger Kockelbergh, Howard Kynaston, Alan Paul, Edgar Paez, Derek J. Rosario, Edward Rowe, Jon Oxley, John Staffurth, David E. Neal, Freddie C. Hamdy, Jenny L. Donovan
Sep 29, 2020
Abstract: Background: There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer. Methods: The cost-effectiveness of active monitoring, surgery, and radiotherapy was evaluated within...
Development and External Validation of the STRATified CANcer Surveillance (STRATCANS) Multivariable Model for Predicting Progression in Men with Newly Diagnosed Prostate Cancer Starting Active Surveillance.
Alexander Light, Artitaya Lophatananon, Alexandra Keates, Vineetha Thankappannair, Tristan Barrett, Jose Dominguez-Escrig, Jose Rubio-Briones, Toufik Benheddi, Jonathan Olivier, Arnauld Villers, Kirthana Babureddy, Haitham Abdelmoteleb, Vincent J Gnanapragasam
Feb 09, 2023
For men with newly diagnosed prostate cancer, we aimed to develop and validate a model to predict the risk of progression on active surveillance (AS), which could inform more personalised AS strategies. In total, 883 men from 3...
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
Sian M. Noble, Kirsty Garfield, J. Athene Lane, Chris Metcalfe, Michael Davis, Eleanor I. Walsh, Richard M. Martin, Emma L. Turner, Tim J. Peters, Joanna C. Thorn, Malcolm Mason, Prasad Bollina, James W. F. Catto, Alan Doherty, Vincent Gnanapragasam, Owen Hughes, Roger Kockelbergh, Howard Kynaston, Alan Paul, Edgar Paez, Derek J. Rosario, Edward Rowe, Jon Oxley, John Staffurth, David E. Neal, Freddie C. Hamdy, Jenny L. Donovan
Jul 28, 2021
Abstract: Background: There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer. Methods: The cost-effectiveness of active monitoring, surgery, and radiotherapy was evaluated within...
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
Sian M Noble, Kirsty Garfield, J Athene Lane, Chris Metcalfe, Michael Davis, Eleanor I Walsh, Richard M Martin, Emma L Turner, Tim J Peters, Joanna C Thorn, Malcolm Mason, Prasad Bollina, James WF Catto, Alan Doherty, Vincent Gnanapragasam, Owen Hughes, Roger Kockelbergh, Howard Kynaston, Alan Paul, Edgar Paez, Derek J Rosario, Edward Rowe, Jon Oxley, John Staffurth, David E Neal, Freddie C Hamdy, Jenny L Donovan
Aug 13, 2020
BACKGROUND: There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer. METHODS: The cost-effectiveness of active monitoring, surgery, and radiotherapy was evaluated within the...
A core outcome set for localised prostate cancer effectiveness trials
S MacLennan, PR Williamson, H Bekema, M Campbell, C Ramsay, J N'Dow, S MacLennan, L Vale, P Dahm, N Mottet, T Lam, G Stewart, COMPACTERS Study Group
Jun 26, 2017
$\textbf{OBJECTIVE}$: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
The Emerging Role of MRI in Prostate Cancer Active Surveillance and Ongoing Challenges.
OBJECTIVE: Active surveillance (AS) has emerged as a management strategy for preventing overtreatment of indolent prostate cancer. Selection of patients for AS has traditionally proved challenging and resulted in 20-30%...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
Current opportunities to catalyze research in nutrition and cancer prevention – an interdisciplinary perspective
The Cancer Research UK - Ludwig Cancer Research Nutrition and Cancer Prevention Collaborative Group
Jul 31, 2019
Cancer Research UK and Ludwig Cancer Research convened an inaugural international Cancer Prevention and Nutrition Conference in London on December 3–4, 2018. Much of the discussion focused on the need for systematic...
cancer prevention Developmental origins Diet EPIDEMIOLOGY epigenetics interdisciplinary metabolism Nutrition obesity physical activity Public Health Biomedical Research Body Weight Congresses as Topic Diet Exercise food Humans Interdisciplinary Communication Interdisciplinary Research Neoplasms Nutrition Therapy Nutritional Status obesity Risk Factors United Kingdom
Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.
Over recent years there has been an increasing awareness that our ideas on the lethality of primary non‐metastatic prostate cancer may need to change. This concept has emerged from a number of different sources including...
Cancer Variant Interpretation Group UK (CanVIG-UK)
Alice Garrett, Alison Callaway, Miranda Durkie, Cankut Cubuk, Mary Alikian, George J Burghel, Rachel Robinson, Louise Izatt, Sabrina Talukdar, Lucy Side, Treena Cranston, Sheila Palmer-Smith, Diana Baralle, Ian R Berry, James Drummond, Andrew J Wallace, Gail Norbury, Diana M Eccles, Sian Ellard, Fiona Lalloo, D Gareth Evans, Emma Woodward, Marc Tischkowitz, Helen Hanson, Clare Turnbull, CanVIG-UK
Mar 16, 2020
Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly; the volume of clinical...
Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care
Julia Wade, Jenny Donovan, Athene Lane, Michael Davis, Eleanor Walsh, David Neal, Emma Turner, Richard Martin, Chris Metcalfe, Tim Peters, Freddie Hamdy, Roger Kockelbergh, James Catto, Alan Paul, Peter Holding, Derek Rosario, Howard Kynaston, Edward Rowe, Owen Hughes, Prasad Bollina, David Gillatt, Alan Doherty, Vincent J Gnanapragasam, Edgar Paez
Sep 11, 2020
Objectives: Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties...
Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care
Julia Wade, Jenny Donovan, Athene Lane, Michael Davis, Eleanor Walsh, David Neal, Emma Turner, Richard Martin, Chris Metcalfe, Tim Peters, Freddie Hamdy, Roger Kockelbergh, James Catto, Alan Paul, Peter Holding, Derek Rosario, Howard Kynaston, Edward Rowe, Owen Hughes, Prasad Bollina, David Gillatt, Alan Doherty, Vincent J Gnanapragasam, Edgar Paez
Nov 26, 2020
OBJECTIVES: Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties...
MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance
Nikita Sushentsev, Leonardo Rundo, Oleg Blyuss, Vincent J. Gnanapragasam, Evis Sala, Tristan Barrett
Jun 21, 2021
Abstract: Nearly half of patients with prostate cancer (PCa) harbour low- or intermediate-risk disease considered suitable for active surveillance (AS). However, up to 44% of patients discontinue AS within the first five years...
The United Kingdom Childhood Cancer Study
UK Childhood Cancer Study Investigators
Feb 21, 2020
An investigation into the possible causes of childhood cancer has been carried out throughout England, Scotland and Wales over the period 1991-1998. All children known to be suffering from one or other type of the disease over...
|
|< |
< |
1 |